The Latest Breaking News from FDA

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

“I hope that this will make people more careful about when they cite studies," one lawyer told Salon

Reports indicate the annual trend of giving up alcohol in January can help increase recreational cannabis sales.

Terry Dubrow, star of Botched, advocates for the use of Ozempic for weight loss, claiming it is safer than Tylenol and effective in treating obesity.

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

The Federal Trade Commission has challenged more than 100 patents drugmakers listed in the FDA’s “Orange Book"

The Supreme Court will soon decide the fate of access for mifepristone. The fallout of a ban would be tremendous

The House approved a bipartisan bill that would expand the child tax credit. As tensions between Zelenskyy and his military chief rise, the EU agrees to more than $50 billion in aid for Ukraine.

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.